

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width.

(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/029431 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US02/31655

(22) International Filing Date: 2 October 2002 (02.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/326,583 2 October 2001 (02.10.2001) US

(71) Applicant: BOARD OF REGENTS - THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventors: BELCHER, Angela, M.; 35 Balfour Street, Lexington, MA 02421 (US). LEE, Seung-Wuk; 3350 Lake Austin Boulevard A, Austin, Texas 78703 (US).

(74) Agents: WARREN, Sanford, E., Jr. et al.; Gardere & Wynne, L.L.P., 3000 Thanksgiving Tower, 1601 Elm Street, Dallas, TX 75201-4761 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GL, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MV, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VU, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GI, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, E, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

- without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: NANOSCALING ORDERING OF HYBRID MATERIALS USING GENETICALLY ENGINEERED MESOSCALE VIRUS

WO 03/029431 A2



Seq ID No 1
Seq ID No 2
Seq ID No 3
Seq ID No 4
Seq ID No 5
Seq ID No 6
Seq ID No 7
Seq ID No 8
Seq ID No 9
Seq ID No 10
Seq ID No 11

BEST AVAILABLE COPY

(57) Abstract: The present invention includes methods for producing nanocrystals of semiconductor material that have specific crystallographic features such as phase and alignment by using a self-assembling biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to semi-conductor material. One form of the present invention is a method to construct ordered nanoparticles within the liquid crystal of the self-assembling biological molecule.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NANOSCALING ORDERING OF HYBRID MATERIALS
USING GENETICALLY ENGINEERED MESOSCALE VIRUS

TECHNICAL FIELD OF THE INVENTION

The present invention is directed to organic materials capable of binding to inorganic materials and specifically, toward bacteriophage that can bind semiconductor materials and form well-ordered structures.

5

BACKGROUND OF THE INVENTION

The research carried out in the subject application was supported in part by grants from the National Science Foundation, the government may own certain rights.

In biological systems, organic molecules exert a remarkable 10 level of control over the nucleation and mineral phase of inorganic materials such as calcium carbonate and silica, and over the assembly of building blocks into complex structures required for biological function.

Materials produced by biological processes are typically 15 soft, and consist of a surprisingly simple collection of molecular building blocks (i.e., lipids, peptides, and nucleic acids) arranged in astoundingly complex architectures. Unlike the semiconductor industry, which relies on a serial lithographic processing approach for constructing the smallest 20 features on an integrated circuit, living organisms execute their architectural "blueprints" using mostly non-covalent forces acting simultaneously upon many molecular components. Furthermore, these structures can often elegantly rearrange between two or more usable forms without changing any of the 25 molecular constituents.

The use of "biological" materials to process the next generation of microelectronic devices provides a possible solution to resolving the limitations of traditional processing methods. The critical factors in this approach are identifying 5 the appropriate compatibilities and combinations of biological-inorganic materials, and the synthesis of the appropriate building blocks.

SUMMARY OF THE INVENTION

The present inventors have designed constructs and produced 10 biological materials that direct and control the assembly of inorganic materials into controlled and sophisticated structures. The use of biological materials to create and design materials that have interesting electrical or optical properties may be used to decrease the size of features and 15 improve the control of, e.g., the opto-electrical properties of the material. Semiconductor materials are typically made from zinc sulfide, gallium arsenide, indium phosphate, cadmium sulfide, aluminum arsenide aluminum stibinide and silicon. These semiconductor materials are often classified into Group 20 III-Group V and Group II -Group VI semiconductor materials.

Organic-inorganic hybrid materials offer new routes to novel materials and devices. The present inventors have exploited the organic-inorganic hybrids to select for peptides that can bind to semiconductor materials. Size controlled 25 nanostructures give optically and electrically tunable properties of semiconductor materials. Using the present invention, organic additives have been used to modify the inorganic morphology, phase, and nucleation direction of semiconductor materials. The monodispersed nature of biological 30 materials makes the system compatible for highly ordered smectic-ordering structure.

Building well-ordered and well-controlled two- and three-dimensional structures at the nanolength scale is the major goal of building next generation optical, electronic and magnetic materials and devices. Many researchers have focused on 5 building such structures using traditional materials approaches. As disclosed herein, the present inventors have demonstrated that soft materials can act as self-organizers that organize inorganic materials at the nanoscale level. Alivisatos and Mirkin have exploited a DNA recognition linker to form specific 10 nanoparticles combination structures. Stupp and Coworkers nucleated ZnS and CdS in lyotropic liquid crystalline media to make nanowires and nanostructures. Both methods, however, are limited in length scale and offer limited types of inorganic materials with which to work. Therefore, alternative methods of 15 creating well-ordered structures at the nanoscale level are needed.

The present invention is based on the recognition that monodisperse biomaterials that have anisotropic shape can be a way to build well-ordered structures. The present invention 20 includes methods for building well-ordered nanoparticle layers by using biological selectivity and self-assembly. The nanoparticle layers can be made of Group II-VI semiconductor materials such as CdS, FeS, and ZnS.

One form of the present invention is a method for using 25 self-assembling biological molecules, e.g., bacteriophage, that are genetically engineered to bind to semi-conductor materials and to organize well-ordered structures. These structures may be, e.g., nanoscale arrays of nanoparticles. Using bacteriophage as an example, self-assembling biological 30 materials can be selected for specific binding properties to particular semiconductor surfaces, and thus, the modified bacteriophage and the methods taught herein may be used to create well-ordered structures of the materials selected.

Another form of the present invention is a method of creating nanoparticles that have specific alignment properties. This is accomplished by creating, e.g., an M13 bacteriophage that has specific binding properties, amplifying the 5 bacteriophage to high concentrations using the polymerase chain reaction, and resuspending the phage.

This same method may be used to create bacteriophage that have three liquid crystalline phases, a directional order in the nematic phase, a twisted nematic structure in the cholesteric 10 phase, and both directional and positional order in smectic phase. In one aspect the present invention is a method of making a polymer, e.g., a film, comprising the steps of, amplifying a self-assembling biological molecule comprising a portion that binds a specific semiconductor surfaces to high 15 concentrations and contacting one or more semiconductor material precursors with the self-assembling biological molecule to form or direct the formation of a crystal.

Another form of the present invention is method for creating nanoparticles that have differing cholesteric pitches 20 by using, e.g., an M13 bacteriophage that has been selected to bind to semiconductor surfaces and resuspending the phage to various concentrations. Another form of the present invention is a method of preparing a casting film with aligned 25 nanoparticles by using, e.g., genetically engineered M13 bacteriophage and re suspending the bacteriophage.

BRIEF DESCRIPTION OF THE FIGURES

For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the 30 accompanying figures in which corresponding numerals in the different figures refer to corresponding parts and in which:

FIGURE 1 depicts selected random amino acid sequences in accordance with the present invention;

FIGURE 2 depicts XPS spectra of structures in accordance with the present invention;

5 FIGURE 3 depicts phage recognition of heterostructures in accordance with the present invention;

FIGURES 4-8 depict specific amino acid sequences in accordance with the present invention;

10 Figures 9(a) and 9(b) depict schematic diagrams of the smectic alignment of M13 phages in accordance with the present invention;

Figures 10(a) - 10(f) are images of the A7-ZnS suspensions: (a) and (b) POM images, (c) AFM image, (d) SEM image, (e) TEM image and (f) TEM image (with electron diffraction insert); and

15 Figures 11(a) - 11(f) are images of the M13 bacteriophage nanoparticle biofilm, (a) photograph of the film, (b) schematic diagram of the film structure, (c) AFM image, (d) SEM image, (e) and (f) TEM images along the x-z and z-y planes.

DETAILED DESCRIPTION OF THE INVENTION

20 Although making and using various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein 25 are merely illustrative of specific ways to make and use the invention, and do not delimit the scope of the invention.

The inventors have previously shown that peptides can bind to semiconductor materials. These peptides have been further developed into a way of nucleating nanoparticles and directing their self-assembly. The main features of the peptides are 5 their ability to recognize and bind technologically important materials with face specificity, to nucleate size-constrained crystalline semiconductor materials, and to control the crystallographic phase of nucleated nanoparticles. The peptides can also control the aspect ratio of the peptides and therefore, 10 the optical properties.

Briefly, the facility with which biological systems assemble immensely complicated structure on an exceedingly minute scale has motivated a great deal of interest in the desire to identify non-biological systems that can behave in a 15 similar fashion. Of particular value would be methods that could be applied to materials with interesting electronic or optical properties, but natural evolution has not selected for interactions between biomolecules and such materials.

The present invention is based on recognition that 20 biological systems efficiently and accurately assemble nanoscale building blocks into complex and functionally sophisticated structures with high perfection, controlled size and compositional uniformity.

One method of providing a random organic polymer pool is 25 using a Phage-display library, based on a combinatorial library of random peptides containing between 7 and 12 amino acids fused to the pIII coat protein of M13 coliphage, provided different peptides that were reacted with crystalline semiconductor structures. Five copies of the pIII coat protein are located on 30 one end of the phage particle, accounting for 10-16 nm of the particle. The phage-display approach provided a physical linkage between the peptide substrate interaction and the DNA

that encodes that interaction. The examples described here used as examples, five different single-crystal semiconductors: GaAs (100), GaAs (111)A, GaAs(111)B, InP(100) and Si(100). These substrates allowed for systematic evaluation of the peptide substrate interactions and confirmation of the general utility of the methodology of the present invention for different crystalline structures.

Protein sequences that successfully bound to the specific crystal were eluted from the surface, amplified by, e.g., a million-fold, and reacted against the substrate under more stringent conditions. This procedure was repeated five times to select the phage in the library with the most specific binding. After, e.g., the third, fourth and fifth rounds of phage selection, crystal-specific phage were isolated and their DNA sequenced. Peptide binding has been identified that is selective for the crystal composition (for example, binding to GaAs but not to Si) and crystalline face (for example, binding to (100) GaAs, but not to (111)B GaAs).

Twenty clones selected from GaAs(100) were analyzed to determine epitope binding domains to the GaAs surface. The partial peptide sequences of the modified pIII or pVIII protein are shown in Figure 1, revealing similar amino-acid sequences among peptides exposed to GaAs. With increasing number of exposures to a GaAs surface, the number of uncharged polar and Lewis-base functional groups increased. Phage clones from third, fourth and fifth round sequencing contained on average 30%, 40% and 44% polar functional groups, respectively, while the fraction of Lewis-base functional groups increased at the same time from 41% to 48% to 55%. The observed increase in Lewis bases, which should constitute only 34% of the functional groups in random 12-mer peptides from our library, suggests that interactions between Lewis bases on the peptides and Lewis-acid

sites on the GaAs surface may mediate the selective binding exhibited by these clones.

The expected structure of the modified 12-mers selected from the library may be an extended conformation, which seems likely for small peptides, making the peptide much longer than the unit cell (5.65 Å) of GaAs. Therefore, only small binding domains would be necessary for the peptide to recognize a GaAs crystal. These short peptide domains, highlighted in Fig. 1, contain serine- and threonine-rich regions in addition to the presence of amine Lewis bases, such as asparagine and glutamine.

To determine the exact binding sequence, the surfaces have been screened with shorter libraries, including 7-mer and disulphide constrained 7-mer libraries. Using these shorter libraries that reduce the size and flexibility of the binding domain, fewer peptide-surface interactions are allowed, yielding the expected increase in the strength of interactions between generations of selection.

Phage, tagged with streptavidin-labeled 20-nm colloidal gold particles bound to the phage through a biotinylated antibody to the M13 coat protein, were used for quantitative assessment of specific binding. X-ray photoelectron spectroscopy (XPS) elemental composition determination was performed, monitoring the phage substrate interaction through the intensity of the gold 4f-electron signal (Figures 2a-c). Without the presence of the G1-3 phage, the antibody and the gold-streptavidin did not bind to the GaAs(100) substrate. The gold-streptavidin binding was, therefore, specific to the phage and an indicator of the phage binding to the substrate. Using XPS it was also found that the G1-3 clone isolated from GaAs(100) bound specifically to GaAs(100) but not to Si(100) (see Figure 2a). In complementary fashion the S1 clone, screened against the (100) Si surface, showed poor binding to the (100) GaAs surface.

Some GaAs clones also bound the surface of InP (100), another zinc-blende structure. The basis of the selective binding, whether it is chemical, structural or electronic, is still under investigation. In addition, the presence of native oxide on the substrate surface may alter the selectivity of peptide binding.

The preferential binding of the G1-3 clone to GaAs(100), over the (111)A (gallium terminated) or (111)B (arsenic terminated) face of GaAs was demonstrated (Fig. 2b, c). The G1-3 clone surface concentration was greater on the (100) surface, which was used for its selection, than on the gallium-rich (111)A or arsenic-rich (111)B surfaces. These different surfaces are known to exhibit different chemical reactivities, and it is not surprising that there is selectivity demonstrated in the phage binding to the various crystal faces. Although the bulk termination of both 111 surfaces give the same geometric structure, the differences between having Ga or As atoms outermost in the surface bilayer become more apparent when comparing surface reconstructions. The composition of the oxides of the various GaAs surfaces is also expected to be different, and this in turn may affect the nature of the peptide binding.

The intensity of Ga 2p electrons against the binding energy from substrates that were exposed to the G1-3 phage clone is plotted in 2c. As expected from the results in Fig. 2b, the Ga 2p intensities observed on the GaAs (100), (111)A and (111)B surfaces are inversely proportional to the gold concentrations. The decrease in Ga 2p intensity on surfaces with higher gold-streptavidin concentrations was due to the increase in surface coverage by the phage. XPS is a surface technique with a sampling depth of approximately 30 angstroms; therefore, as the thickness of the organic layer increases, the signal from the inorganic substrate decreases. This observation was used to

confirm that the intensity of gold-streptavidin was indeed due to the presence of phage containing a crystal specific bonding sequence on the surface of GaAs. Binding studies were performed that correlate with the XPS data, where equal numbers of 5 specific phage clones were exposed to various semiconductor substrates with equal surface areas. Wild-type clones (no random peptide insert) did not bind to GaAs (no plaques were detected). For the G1-3 clone, the eluted phage population was 12 times greater from GaAs(100) than from the GaAs(111)A 10 surface.

The G1-3, G12-3 and G7-4 clones bound to GaAs(100) and InP(100) were imaged using atomic force microscopy (AFM). The InP crystal has a zinc-blende structure, isostructural with GaAs, although the In-P bond has greater ionic character than 15 the GaAs bond. The 10-nm width and 900-nm length of the observed phage in AFM matches the dimensions of the M13 phage observed by transmission electron microscopy (TEM), and the gold spheres bound to M13 antibodies were observed bound to the phage (data not shown). The InP surface has a high concentration of 20 phage. These data suggest that many factors are involved in substrate recognition, including atom size, charge, polarity and crystal structure.

The G1-3 clone (negatively stained) is seen bound to a GaAs crystalline wafer in the TEM image (not shown). The data 25 confirms that binding was directed by the modified pIII protein of G1-3, not through non-specific interactions with the major coat protein. Therefore, peptides of the present invention may be used to direct specific peptide-semiconductor interactions in assembling nanostructures and heterostructures (Fig. 4e).

30 X-ray fluorescence microscopy was used to demonstrate the preferential attachment of phage to a zinc-blende surface in close proximity to a surface of differing chemical and

structural composition. A nested square pattern was etched into a GaAs wafer; this pattern contained 1- μm lines of GaAs, and 4- μm SiO₂ spacing in between each line (Figs. 3a, 3b). The G12-3 clones were interacted with the GaAs/SiO₂ patterned substrate, 5 washed to reduce non-specific binding, and tagged with an immuno-fluorescent probe, tetramethyl rhodamine (TMR). The tagged phage were found as the three red lines and the center dot, in Fig. 3b, corresponding to G12-3 binding only to GaAs. The SiO₂ regions of the pattern remain unbound by phage and are 10 dark in color. This result was not observed on a control that was not exposed to phage, but was exposed to the primary antibody and TMR (Fig. 3a). The same result was obtained using 15 non-phage bound G12-3 peptide.

The GaAs clone G12-3 was observed to be substrate-specific for GaAs over AlGaAs (Fig. 3c). AlAs and GaAs have essentially identical lattice constraints at room temperature, 5.66 Å° and 5.65 Å°, respectively, and thus ternary alloys of Al_xGa_{1-x}As can be epitaxially grown on GaAs substrates. GaAs and AlGaAs have zinc-blende crystal structures, but the G12-3 clone exhibited 20 selectivity in binding only to GaAs. A multilayer substrate was used, consisting of alternating layers of GaAs and of Al_{0.98}Ga_{0.02}As. The substrate material was cleaved and subsequently reacted with the G12-3 clone.

The G12-3 clones were labeled with 20-nm gold-streptavidin 25 nanoparticles. Examination by scanning electron microscopy (SEM) shows the alternating layers of GaAs and Al_{0.98}Ga_{0.02}As within the heterostructure (Fig. 3c). X-ray elemental analysis of gallium and aluminum was used to map the gold-streptavidin particles exclusively to the GaAs layers of the heterostructure, 30 demonstrating the high degree of binding specificity for chemical composition. In Fig. 3d, a model is depicted for the

discrimination of phage for semiconductor heterostructures, as seen in the fluorescence and SEM images (Figs 3a-c).

The present invention demonstrates the power use of phage-display libraries to identify, develop and amplify binding between organic peptide sequences and inorganic semiconductor substrates. This peptide recognition and specificity of inorganic crystals has been extended to other substrates, including GaN, ZnS, CdS, Fe₃O₄, Fe₂O₃, CdSe, ZnSe and CaCO₃ using peptide libraries. Bivalent synthetic peptides with two-component recognition (Fig. 4e) are currently being designed; such peptides have the potential to direct nanoparticles to specific locations on a semiconductor structure. These organic and inorganic pairs should provide powerful building blocks for the fabrication of a new generation of complex, sophisticated electronic structures.

Example I

Peptide Creation, Isolation, Selection and Characterization

Peptide selection. The phage display or peptide library was contacted with the semiconductor, or other, crystals in Tris-buffered saline (TBS) containing 0.1% TWEEN-20, to reduce phage-phage interactions on the surface. After rocking for 1 h at room temperature, the surfaces were washed with 10 exposures to Tris-buffered saline, pH 7.5, and increasing TWEEN-20 concentrations from 0.1% to 0.5%(v/v). The phage were eluted from the surface by the addition of glycine-HCl (pH 2.2) 10 minute, transferred to a fresh tube and then neutralized with Tris-HCl (pH 9.1). The eluted phage were titered and binding efficiency was compared.

The phage eluted after third-round substrate exposure were mixed with their *Escherichia coli* ER2537 host and plated on LB

XGal/IPTG plates. Since the library phage were derived from the vector M13mp19, which carries the lacZ α gene, phage plaques were blue in color when plated on media containing Xgal (5-bromo-4-chloro-3-indoyl- β -D-galactoside) and IPTG (isopropyl- β -D-thiogalactoside). Blue/white screening was used to select phage plaques with the random peptide insert. Plaques were picked and DNA sequenced from these plates.

Substrate preparation. Substrate orientations were confirmed by X-ray diffraction, and native oxides were removed by appropriate chemical specific etching. The following etches were tested on GaAs and InP surfaces: NH₄OH: H₂O 1:10, HCl:H₂O 1:10, H₃PO₄: H₂O₂: H₂O 3:1:50 at 1 minute and 10 minute etch times. The best element ratio and least oxide formation (using XPS) for GaAs and InP etched surfaces was achieved using HCl: H₂O for 1 minute followed by a deionized water rinse for 1 minute. However, since an ammonium hydroxide etch was used for GaAs in the initial screening of the library, this etch was used for all other GaAs substrate examples. Si(100) wafers were etched in a solution of HF:H₂O 1:40 for one minute, followed by a deionized water rinse. All surfaces were taken directly from the rinse solution and immediately introduced to the phage library. Surfaces of control substrates, not exposed to phage, were characterized and mapped for effectiveness of the etching process and morphology of surfaces by AFM and XPS.

Multilayer substrates of GaAs and of Al_{0.98}Ga_{0.02} As were grown by molecular beam epitaxy onto (100) GaAs. The epitaxially grown layers were Si-doped (n-type) at a level of 5 x 10¹⁷ cm⁻³.

Antibody and Gold Labeling. For the XPS, SEM and AFM examples, substrates were exposed to phage for 1 h in Tris-buffered saline then introduced to an anti-fd bacteriophage-biotin conjugate, an antibody to the pIII protein of fd phage, (1:500 in phosphate buffer, Sigma) for 30 minute and then rinsed

in phosphate buffer. A streptavidin/20-nm colloidal gold label (1:200 in phosphate buffered saline (PBS), Sigma) was attached to the biotin-conjugated phage through a biotin-streptavidin interaction; the surfaces were exposed to the label for 30 minutes and then rinsed several times with PBS.

X-ray Photoelectron Spectroscopy (XPS). The following controls were done for the XPS examples to ensure that the gold signal seen in XPS was from gold bound to the phage and not non-specific antibody interaction with the GaAs surface. The prepared (100) GaAs surface was exposed to (1) antibody and the streptavidin-gold label, but without phage, (2) G1-3 phage and streptavidin-gold label, but without the antibody, and (3) streptavidin-gold label, without either G1-3 phage or antibody.

The XPS instrument used was a Physical Electronics Phi ESCA 5700 with an aluminum anode producing monochromatic 1,487-eV X-rays. All samples were introduced to the chamber immediately after gold-tagging the phage (as described above) to limit oxidation of the GaAs surfaces, and then pumped overnight at high vacuum to reduce sample outgassing in the XPS chamber.

Atomic Force Microscopy (AFM). The AFM used was a Digital Instruments Bioscope mounted on a Zeiss Axiovert 100s-2tv, operating in tip scanning mode with a G scanner. The images were taken in air using tapping mode. The AFM probes were etched silicon with 125-mm cantilevers and spring constants of 20 ± 100 Nm⁻¹ driven near their resonant frequency of 200 ± 400 kHz. Scan rates were of the order of 1 ± 5 mms⁻¹. Images were leveled using a first-order plane to remove sample tilt.

Transmission Electron Microscopy (TEM). TEM images were taken using a Philips EM208 at 60 kV. The G1-3 phage (diluted 1:100 in TBS) were incubated with GaAs pieces (500 nm) for 30 minute, centrifuged to separate particles from unbound phage,

rinsed with TBS, and resuspended in TBS. Samples were stained with 2% uranyl acetate.

Scanning Electron Microscopy (SEM). The G12-3 phage (diluted 1:100 in TBS) were incubated with a freshly cleaved 5 hetero-structure surface for 30 minute and rinsed with TBS. The G12-3 phage were tagged with 20-nm colloidal gold. SEM and elemental mapping images were collected using the Norian detection system mounted on a Hitachi 4700 field emission scanning electron microscope at 5 kV.

10 EXAMPLE II BIOFILMS

The present inventors have recognized that organic-inorganic hybrid materials offer new routes for novel materials and devices. Size controlled nanostructures give optically and electrically tunable properties of semiconductor materials and 15 organic additives modify the inorganic morphology, phase, and nucleation direction. The monodispersed nature of biological materials makes the system compatible for highly ordered smectic-ordering structure. Using the methods of the present invention, highly ordered nanometer scale as well as multi-length scale alignment of II-VI semiconductor material using 20 genetically engineered, self-assembling, biological molecules, e.g., M13 bacteriophage that have a recognition moiety of specific semiconductor surfaces were created.

Using the compositions and methods of the present invention 25 nano- and multi-length scale alignment of semiconductor materials was achieved using the recognition and self-ordering system described herein. The recognition and self-ordering of semiconductors may be used to enhance micro fabrication of electronic devices that surpass current photolithographic 30 capabilities. Application of these materials include: optoelectronic devices such as light emitting displays, optical

detectors and lasers; fast interconnects; and nano-meter scale computer components and biological sensors. Other uses of the biofilms created using the present invention include well-ordered liquid crystal displays and organic-inorganic display
5 technology.

The films, fibers and other structures may even include high density sensors for detection of small molecules including biological toxins. Other uses include optical coatings and optical switches. Optionally, scaffoldings for medical implants
10 or even bone implants; may be constructed using one or more of the materials disclosed herein, in single or multiple layers or even in striations or combinations of any of these, as will be apparent to those of skill in the art. Other uses for the present invention include electrical and magnetic interfaces, or
15 even the organization of 3D electronic nanostructures for high density storage, e.g., for use in quantum computing. Alternatively, high density and stable storage of viruses for medical application that can be reconstituted, e.g., biologically compatible vaccines, adjuvants and vaccine
20 containers may be created with the films and or matrices created with the present invention. Information storage based on quantum dot patterns for identification, e.g., department of defense friend or foe identification in fabric of armor or coding. The present nanofibers may even be used to code and
25 identify money.

Building well-ordered, well-controlled, two and three dimensional structure at the nanolength scale is the major goal of building next generation optical, electronic and magnetic materials and devices. Current methods of making specific
30 nanoparticles are limited in terms of both length scale and the types of materials. The present invention exploits the properties of self-assembling organic or biological molecules or particles, e.g., M13 bacteriophage to expand the alignment,

size, and scale of the nanoparticles as well as the range of semiconductor materials that can be used.

The present inventors have recognized that monodisperse biomaterials having anisotropic shapes are an alternative way 5 to build well-ordered structures. Nano and multi-length scale alignment of II-VI semiconductor material was accomplished using genetically engineered M13 bacteriophage that possess a recognition moiety (a peptide or amino acid oligomer) for specific semiconductor surfaces.

10 Seth and coworkers have characterized Fd virus smectic ordering structures that have both a positional and directional order. The smectic structure of Fd virus has potential application in both multi-scale and nanoscale ordering of structures to build 2-dimensional and 3-dimensional alignment of 15 nanoparticles. Bacteriophage M13 was used because it can be genetically modified, has been successfully selected to have a shape identical to the Fd virus, and has specific binding affinities for II-VI semiconductor surfaces. Therefore, M13 is an ideal source for smectic structure that can serve in multi- 20 scale and nanoscale ordering of nanoparticles.

The present inventors have used combinatorial screening methods to find M13 bacteriophage containing peptide inserts that are capable of binding to semiconductor surfaces. These semiconductor surfaces included materials such as zinc sulfide, 25 cadmium sulfide and iron sulfide. Using the techniques of molecular biology, bacteriophage combinatorial library clones that bind specific semi-conductor materials and material surfaces were cloned and amplified up to concentrations high enough for liquid crystal formation.

30 The filamentous bacteriophage, Fd, has a long rod shape (length: 880 nm; diameter: 6.6 nm) and monodisperse molecular

weight (molecular weight: 1.64×10^7). These properties result in the bacteriophage's lyotropic liquid crystalline behavior in highly concentrated solutions. The anisotropic shape of bacteriophage was exploited as a method to build well-ordered nanoparticle layers by use of biological selectivity and self-assembly. Monodisperse bacteriophage were prepared through standard amplification methods. In the present invention, M13, a similar filamentous bacteriophage, was genetically modified to bind nanoparticles such as zinc sulfide, cadmium sulfide and iron sulfide.

Mesoscale ordering of bacteriophage has been demonstrated to form nanoscale arrays of nanoparticles. These nanoparticles are further organized into micron domains and into centimeter length scales. The semiconductor nanoparticles show quantum confinement effects, and can be synthesized and ordered within the liquid crystal.

Bacteriophage M13 suspension containing specific peptide inserts were made and characterized using Atomic Force Microscopy (AFM), Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM). Uniform 2D and 3D ordering of nanoparticles was observed throughout the samples.

Atomic Force Microscopy (AFM). The AFM used was a Digital Instruments Bioscope mounted on a Zeiss Axiovert 100s-2tv, operating in tip scanning mode with a G scanner. The images were taken in air using tapping mode. The AFM probes were etched silicon with 125-mm cantilevers and spring constants of $20 \pm 100 \text{ Nm}^{-1}$ driven near their resonant frequency of $200 \pm 400 \text{ kHz}$. Scan rates were of the order of $1 \pm 5 \text{ mms}^{-1}$. Images were leveled using a first-order plane to remove sample tilt. Figures 9(a) and 9(b) are schematic diagrams of the smetic alignment of M13 phages observed using AFM (data not shown).

Transmission Electron Microscopy (TEM). TEM images were taken using a Philips EM208 at 60 kV. The G1-3 phage (diluted 1:100 in TBS) were incubated with semiconductor material for 30 minute, centrifuged to separate particles from unbound phage, 5 rinsed with TBS, and resuspended in TBS. Samples were stained with 2% uranyl acetate.

Scanning Electron Microscopy (SEM). The phage (diluted 1:100 in TBS) were incubated with a freshly cleaved hetero-structure surface for 30 minute and rinsed with TBS. The G12-3 10 phage were tagged with 20-nm colloidal gold. SEM and elemental mapping images were collected using the Norian detection system mounted on a Hitachi 4700 field emission scanning electron microscope at 5 kV.

Genetically engineered M13 bacteriophage that had specific 15 binding properties to semiconductor surfaces was amplified and purified using standard molecular biological techniques. 3.2 ml of bacteriophage suspension (concentration: $\sim 10^7$ phages/ μ l) and 4 ml of overnight culture were added to 400 ml LB medium for mass amplification. After amplification, ~ 30 mg of pellet was 20 precipitated. The suspensions were prepared by adding Na₂S solutions to ZnCl₂ doped A7 phage suspensions at room temperature. The highest concentration of A7-phage suspension was prepared by adding 20 μ l of 1 mM ZnCl₂ and Na₂S solutions, respectively into the ~ 30 mg of phage pellet. The concentration 25 was measured using extinction coefficient of 3.84mg/ml at 269 nm.

As the concentration of the isotropic suspension is increased, nemetic phase that has directional order, cholesteric phase that has twisted nemetic structure, and smectic phase that 30 has directional and positional orders as well, are observed. These phases had been observed in Fd viruses that did not have nanoparticles.

Polarized optical microscopy: M13 phage suspensions were characterized by polarized optical microscope. Each suspension was filled to glass capillary tube of 0.7 mm diameter. The highly concentrated suspension (127 mg/ml) exhibited iridescent color [5] under the paralleled polarized light and showed smectic texture under the cross-polarized light as Fig. 10(a). The cholesteric pitches, Fig. 10(b) can be controlled by varying the concentration of suspension as Table 1. The pitch length was measured and the micrographs were taken after 24 hours later from the preparation of samples.

Table 1. Cholesteric pitch and concentration relationship

Concentration (mg/ml)	Pitch length (um)
76.30	31.9
71.22	51.6
56.38	84.8
50.52	101.9
43.16	163.7
37.04	176.1
27.54	259.7

Atomic Force Microscope (AFM) observation: For AFM observation, 5 ul of M13 suspension (concentration: 30mg/ml) of M13 bacteriophage suspension was dried for 24 hours on the 8 mm x 8 mm mica substrate that was silated by 3-amino propyl triethyl silane for 4 hours in the dessicator. Images were taken in air using tapping mode. Self-assembled ordering structures were observed due to the anisotropic shape of M13 bacteriophage, 880 nm in length and 6.6 nm in width. In Fig.10 (c) M13 phage lie in the plane of the photo and form smectic alignment.

Scanning electron microscope (SEM) observation: For SEM observation, the critical point drying samples of bacteriophage and ZnS nanoparticles smectic suspension (concentration of bacteriophage suspension 127mg/ml) were prepared. In Fig.

10(d), nanoparticles rich areas and bacteriophage rich areas were observed. The length of the separation between nanoparticles and bacteriophage correspond to the length of bacteriophage. The ZnS wurzite crystal structure was confirmed
5 by electron diffraction pattern using dilution sample of the smectic suspension with TEM.

Preparation of the biofilm: Bacteriophage pellets were suspended with 400 ul of Tris-buffered saline (TBS, pH 7.5) and 200 ul of 1 mM ZnCl₂ to which 1mM Na₂S was added. After rocking
10 for 24 hours at room temperature, the suspension which was contained in a 1 ml eppendorff tube, was slowly dried in a dessicator for one week. A semi-transparent film ~15 um thick was formed on the inside of the tube. This film, Fig. 11(a), was carefully taken using a tweezers.

15 SEM observation of biofilm: Nanoscale bacteriophage alignment of the A7-ZnS film were observed using SEM. In order to carry out SEM analysis the film was cut then coated via vacuum deposition with 2 nm of chromium in an argon atmosphere. Highly close-packed structures, Fig 11(d) were observed
20 throughout the sample. The average length of individual phage, 895 nm is reasonable analogous to that of phage, 880 nm. The film showed the smectic like A or C like lamellar morphologies that exhibited periodicity between the nanoparticle and bacteriophage layers. The length of periodicity corresponded to
25 that of the bacteriophage. The average size of nanoparticle is ~20nm analogous to the TEM observation of individual particles.

TEM observation of biofilm: ZnS nanoparticle alignment was investigated using TEM. The film was embedded in epoxy resin (LR white) for one day and polymerized by adding 10 ul of
30 accelerator. After curing, the resin was thin sectioned using a Leica Ultramicrotome. These ~ 50 nm sections were floated on distilled water, and picked up on blank gold grids. Parallel-

aligned nanoparticles in a low, which corresponded to x-z plane in the schematic diagram, were observed, Fig. 11(e). Since each bacteriophage had 5 copies of the A7 moieties, each A7 recognize one nanoparticle(2~3 nm size) and aligned approximately 20 nm in 5 a width and extended to more than two micrometers in length. The two micrometers by 20 nm bands formed in parallel each band separated by ~700 nm. This discrepancy may come from the tilted smectic alignment of the phage layers with respect to observation in the TEM, which is reported by Marvin group. A y- 10 z axis like nanoparticle layer plane was also observed like Fig 3 (f). The SAED patterns of the aligned particles showed that the ZnS particles have the wurzite hexagonal structure.

AFM observation of biofilm: The surface orientation of the viral film was investigated using AFM. In Fig 11. (c), the 15 phage were shown to have formed an parallel aligned herringbone pattern that have almost right angle between the adjacent director normal(bacteriophage axis) on most of surface that is named as smectic O. The film showed long range ordering of normal director that is persistent to the tens of micrometers. 20 In some of areas where two domain layers meet each other, two or three multi-length scale of bacteriophage aligned paralleled and persistent to the smectic C ordering structure.

Nano and multi-length scale alignment of semiconductor materials using the recognition and as well as self-ordering 25 system enhances the future microfabrication of electronic devices. These devices have the potential to surpass current photolithographic capabilities. Other potential applications of these materials include optoelectronic devices such as light-emitting displays, optical detectors, and lasers, fast 30 interconnects, nano-meter scale computer component and biological sensors.

Although making and using various embodiments of the present invention are discussed in detail below, it will be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention, and do not delimit the scope of the invention.

What is claimed is:

1. A method of making a film comprising the steps of:

amplifying a self-assembling biological molecule comprising a portion that binds a specific semiconductor surfaces to high concentrations; and

5 contacting a semiconductor material precursor with the self-assembling biological molecule to form a crystal.

2. The method recited in claim 1 wherein the self-assembling biological molecule has been engineered to expose one or more amino acid oligomers on its surface.

10 3. The method recited in claim 2 wherein the oligomer is between 7 and 15 amino acids long.

4. The method recited in claim 1 wherein the selection of self-assembling biological molecule is accomplished by combinatorial library screening.

15 5. The method recited in claim 4 wherein the screening comprising the steps of eluting the bound self-assembling biological molecule from the crystal.

20 6. The method recited in claim 5 further comprising the step of contacting the eluted amino acid oligomer with the semiconductor material; and

repeating the eluting step.

7. The method recited in claim 6 wherein the binding and eluting is repeated up to five times.

8. The method recited in claim 1 wherein the self-assembling biological molecule is amplified up to liquid crystal concentrations.

9. The method recited in claim 8 wherein the amplification
5 is accomplished using the polymerase chain reaction.

10. The method recited in claim 1 wherein the semiconductor material comprises II-IV semiconductor material.

11. A method of controlling the cholesteric pitch of a nanoparticle comprising the steps of:

10 amplifying a self-assembling viral particle comprising a portion that binds a specific semiconductor surfaces to high concentrations; and

contacting a semiconductor material precursor with the self-assembling viral particle to form a crystal.

15 12. The method recited in claim 11 wherein the self-assembling viral particle has been engineered to expose one or more amino acid oligomers on its surface.

13. The method recited in claim 12 wherein the oligomer is between 7 and 15 amino acids long.

20 14. The method recited in claim 12 wherein the selection of the self-assembling viral particle is accomplished by combinatorial library screening.

15. The method recited in claim 14 wherein the screening comprises the steps of:

contacting the self-assembling viral particle containing the amino acid oligomer to one or more crystals of the semiconductor material so that the one or more crystals may bind.

16. The method recited in claim 15 further comprising the step of contacting the eluted amino acid oligomer with the semiconductor material; and

repeating the eluting step.

10 17. The method recited in claim 16 wherein the binding and eluting is repeated up to five times.

18. The method recited in claim 12 wherein the self-assembling viral particle is amplified up to liquid crystal concentrations.

15 19. The method recited in claim 18 wherein the amplification is accomplished using the polymerase chain reaction.

20. The method recited in claim 12 wherein the semiconductor material comprises II-IV semiconductor material.

21. The method recited in claim 12 wherein the method is used 20 to control the smectic alignment of the nanoparticle.

22. The method recited in claim 12 wherein the method is used to impart nematic phase to the nanoparticle.

23. The method recited in claim 12 wherein the method is used to produce a casting film.

5 24. A film made by the method of claim 1.

25. A film made by the method of claim 11.

26. A method of making a nanoparticle comprising the steps of:

fixing a semiconductor binding peptide to a substrate;

10 contacting one or more semiconductor material precursors with the semiconductor binding peptide; and

forming a semiconductor crystal on the semiconductor binding peptide.

27. The method of claim 26, wherein the semiconductor binding 15 peptide further comprises a chimeric protein that exposes one or more amino acid oligomers on its surface.

28. The method of claim 26, wherein the semiconductor binding peptide comprises between about 7 and 15 amino acids.

29. The method of claim 26, further comprising the step of 20 eluting the semiconductor crystal from the semiconductor binding.

30. The method of claim 26, wherein the semiconductor binding peptide is linked chemically to the substrate.

31. The method of claim 26, wherein the semiconductor binding 25 peptide comprises a chimeric protein with a self-assembling viral particle.

32. The method of claim 26, wherein the semiconductor material comprises a Group II-IV semiconductor material.

33. The method of claim 26, wherein the semiconductor binding peptide controls the smectic alignment of a nanoparticle.

30 34. The method of claim 26, wherein the semiconductor binding peptide controls the nematic phase of a nanoparticle.

35. The method of claim 26, wherein the method is used to produce a film.

36. A polymer made by the method of claim 26.






Fig 1



F15 2



FIS 3

CdS Single Crystal

12-mer library

CEF-81	E1	Ser	Leu		Asn	Ser	Aa						Seq ID No 12
CEF-82	E2	Ser	Leu		Asn	Ser	Aa						Seq ID No 13
CEF-83	E3	Ser	Leu		Asn	Ser	Aa						Seq ID No 14
CEF-84	E4	Ser	Leu		Asp	Ser	Aa						Seq ID No 15
CEF-85	E5	Ser	Leu		Asp	Ser	Aa						Seq ID No 16
CEF-86	E6	Ser	Leu		Asp	Ser	Aa						Seq ID No 17
CEF-88	E8	Ser	Leu		Asp	Ser	Aa						Seq ID No 18
CEF-89	E9	Ser	Leu		Asp	Ser	Aa						Seq ID No 19
CEF-90	E10	Ser	Leu		Asp	Ser	Aa						Seq ID No 20
CEF-91	E11	Ser	Leu		Asp	Ser	Aa						Seq ID No 21
CEF-92	E12	Ser	Leu		Asp	Ser	Aa						Seq ID No 22
CEF-159	E13	Pro	Leu	Met	Thr	Met		Ser	Asp		Met	Ser	SID 03
CEF-160	E14	Pro	Ala	Leu	Pro	Thr	Pro	Ala	Pro	Thr	Phe	Thr	SID 04
CEF-161	E15	Ser	Ala	Leu	Gln	Ser	Thr	Leu	Asn	Ser	Ser	Met	SID 05
CEF-162	E16	Pro	Gly	Ala	Thr	Ala	Arg	Leu	Arg	Ala	Leu	Met	SID 06
CEF-163	E18	Thr	Ala	Val	Pro	Ser	Met	Leu	Leu	Thr	Thr	Gln	SID 07
CEF-164	E19	Val	Gly	Leu	Pro	Gly	Val	Gln	Gln	Asn	Pro	Ser	Ala
CEF-165	E20	Phe	Arg	Ala	Val	Tyr	Gln	Leu	Pro	Ser	Thr	Thr	Leu
CEF-166	E21	Ile	Pro	Arg	Ser	Pro	Met	Gln	Ile	Val	Ser	Ile	Gln
CEF-167	E22	Tyr	Pro	Ser		Val	Ile	Leu	Asn	Arg		Met	Ser
CEF-168	E23	wt											
CEF-169	E24	Met	Pro	Trp	Ala	Leu	Gln	Asp	Ala	Ile	Pro	Met	Gln
CEF-170	E25	Pro	Thr	Leu	Pro	Arg	Arg	Ile		Leu	Asn	Gln	Thr
CEF-171	E26	Ile	Pro	Arg	Ser	Pro	Met	Gln	Ile	Ala	Ser	Ile	Gln
CEF-172	E27	Leu	Gln	Tyr	Pro	Tyr	Pro	Ser	Pro	Ser	Met	Pro	Tyr
CEF-173	E28	Ser	Pro	Pro	Leu	Pro	Thr	Pro	Gln	Ile	Met	Phenyl	Ser
CEF-174	E29	Ala	Ser	Asn	Leu	Ser	Thr	Ile	Thr	Pro	Ala	Leu	Gly
CEF-175	E30	Ser	Ala	Asn	Leu	Tyr	Pro	Ile	Val	Pro	Phenyl	Gln	Met

Fig 4

CdS	Biopan 3 Sequences								
JCW-96									SIV 39
JCW-97									SIV 40
JCW-98									SIV 41
JCW-99									SIV 42
JCW-100									SIV 43
JCW-101									SIV 44
JCW-102									SIV 45
JCW-103									SIV 46
JCW-104									SIV 47
JCW-105									SIV 48
CdS	Biopan 4 Sequences								
JCW-106									SIV 49
JCW-108									SIV 50
JCW-111									SIV 51
CdS	Biopan 5 Sequences								
JCW-118									SIV 52
JCW-122									SIV 53
CdS	Biopan 3 Sequences (repeat)								
JCW-125									SIV 54
JCW-126									SIV 55
JCW-127									SIV 56
JCW-128									SIV 57
JCW-129									SIV 58
JCW-130									SIV 59
JCW-131									SIV 60
JCW-132	WT								
JCW-133									SIV 61
JCW-134									SIV 62
CdS	Biopan 2 Sequences								
JCW-137									SIV 63
JCW-139									SIV 64
JCW-140									SIV 65
JCW-141									SIV 66
CdS	Biopan 5 Sequences (repeat)								
JCW-146									SIV 67
JCW-148									SIV 68

Fig 5

some other arrangements

4	B71	CEF-215	[A] S I P A S T P R G M Q E D Q	SID 69
4	G	CEF-156	[I] E T I V A P R I S P R O F H C	SID 70
3t	H13	CEF-131	[A] V I P C I P C I L E U P A S T P	SID 71
3t	H15	CEF-133	[V] A P C I P C I L E U P A S T P	SID 72
3t	H14	CEF-132	[V] E P V A P C I L E U P A S T P	SID 73
3	B49	CEF-203	[E] P V A P C I L E U P A S T P	SID 74
3t	H2	CEF-120	[A] P C I L E U P A S T P A V A	SID 75
3	G4	CEF-102	[A] I P C I L E U P A S T P A V A	SID 76
3t	H17	CEF-135	[A] I P C I L E U P A S T P A V A	SID 77
4		B20	[P] C I L E U P A S T P A V A	SID 78
5	CEF-27	B29	[P] C I L E U P A S T P A V A	SID 79
3	G2	CEF-100	[A] I P C I L E U P A S T P A V A	SID 80
3	B48	CEF-202	[A] I P C I L E U P A S T P A V A	SID 81
3a	B92	CEF-229	[A] I P C I L E U P A S T P A V A	SID 82

net-pro sequences from Aldrich ZnS screenings

3a	B63	CEF-207	[I] S Met Pro Gln Ile Val Asn	SID 83
4		B18	[G] F A S H S e r A Met Pro Phe	SID 84
4a	B73	CEF-217	[F] A S H S e r A Met Pro Ser Gln	SID 85
5		B7	[A] S D I G H I L Met Pro A S T A S M	SID 86
5	CEF-28	B30	[A] S D I G H I L Pro Met Ser Gln	SID 87
5	CEF-34	B36	[G] H I L Pro Met Ser Gln	SID 88
5	CEF-35	B37	[A] S D I G H I L Pro Met Ser Gln	SID 89
		JCW-87	[I] I Gln Ile Met Pro A S D I H e t I s t V a l H s	SID 90
		JCW-87	[I] I Gln Ile Met Pro A S D I H e t I s t V a l H s	SID 91
5	JCW-65	5H7	[I] I Gln Ile A S M I e t P r o H e t I s t M e t A S M P r o L e u	SID 92
4	JCW-57	4H9	[M] e t I I G l n P r o M e t P r o L e u A c t I e u P r o L e u	SID 93
4	JCW-30	437-10	[P] h e t I I G l n P r o M e t P r o L e u A c t I e u M e t S a l	SID 94
4	JCW-28	437-8	[P] h e t I I G l n P r o M e t P r o L e u A c t I e u M e t S a l	SID 95
4	JCW-21	437-1	[P] r o L e u A c t I I G l n M e t P h e r S e r A l a n I e u	SID 96
4	JCW-22	437-2	[P] r o A c t I I G l n M e t A l a M e t G l n I v t S e r P r o P r o	SID 97
4	JCW-23	437-3	[P] r o I I G l n S e r A l a M e t A s t I b u N t S e r W y t G l n	SID 98
3	JCW-3	337-3	[P] r o I I G l n S e r A l a M e t A s t I b u N t S e r W y t G l n	SID 99
5	CEF-11	Z35	[P] r o A c t S e r P r o M e t G l n V a l S e r V a l S e r	SID 100
5	CEF-6	Z30	[L] e u I I A c t I I G l n A s t P h e P r o L e u I I S u M e t	SID 101
5	CEF-3	Z27	[L] e u I I A c t I I G l n A s t P h e S e r P r o I I M e t P r o L e u	SID 102
5		Z22	[V] a l I I S e r G l n A s t A l a P r o P r o S e r V a l M e t	SID 103
5		Z23	[A] c t I I G l n A s t A l a M e t L e u I I I t G l n P r o G l n	SID 104
5		Z15	[A] c t I I G l n A s t A l a M e t G l n V a l I I I t A l a H s M e t S e r	SID 105
5	Z9	I1	[A] c t I I G l n A s t M e t P r o I I I t A l a H s M e t S e r	SID 106
5	Z10	I2	[L] e u P r o A c t A l a P h e M e t G l n I I I t A l a P r o G l n S e r	SID 107
2	Z4	I3	[M] e t L e u G l n A l a S e r G l n P r o Z n K s n A l a I l e	SID 108
		C16	[A] l a I I P r o G l n I I I t M e t V a l	SID 109
		C10	[L] e u S e r I I I t P r o A c t M e t I I I t	SID 110

Fig 6

ZnS capping experiments

		BPS													
Z6			[Gly]	[Val]	[Ser]	[Pro]	[Ser]	[Gly]	[Val]	[Ser]	[Asp]	[Leu]	SID 111		
Z8			[Gly]	[Val]	[Ser]	[Pro]	[Ser]	[Gly]	[Val]	[Ser]	[Asp]	[Leu]	SID 112		
Z10			[Ala]	[Pro]	[Val]	[Asp]	[Pro]	[Met]	[Gly]	[Val]	[Asp]	[Pro]	[Ser]	SID 113	
ZnS 12-mer repeats															
5	JCW-44	537-4	[Pro]	[Pro]	[Ser]	[Pro]	[Ser]	[Met]	[Gly]	[Val]	[Ser]	[Asp]	[Ser]	SID 114	
4	JCW-28	437-8	[Pro]	[Pro]	[Ser]	[Pro]	[Ser]	[Met]	[Gly]	[Val]	[Ser]	[Asp]	[Ser]	SID 115	
5	CEF-11	Z35	[Pro]	[Asp]	[Pro]	[Ser]	[Pro]	[Met]	[Gly]	[Val]	[Asp]	[Val]	[Ser]	SID 116	
CdS contamin	1	CEF-83	E3	[Pro]	[Ser]	[Val]	[Asp]	[Ser]	[Ala]	[Gly]	[Val]	[Asp]	[Ser]	SID 117	
PbS 7-mer ref	4	JCW-72	P74-4	[Gly]	[Asp]	[Pro]	[Ile]	[Ser]	[Asp]	[Gly]	[Val]	[Ser]	[Asp]	SID 118	
	4	JCW-74	P74-6	[Gly]	[Asp]	[Pro]	[Ile]	[Ser]	[Asp]	[Gly]	[Val]	[Ser]	[Asp]	SID 119	
5	JCW-76	P75-2	[Pro]	[Pro]	[Ser]	[Val]	[Pro]	[Ala]	[Leu]	[Pro]	[Val]	[Ser]	[Asp]	SID 120	
	5	JCW-78	P75-4	[Pro]	[Pro]	[Ser]	[Val]	[Pro]	[Ala]	[Leu]	[Pro]	[Val]	[Ser]	[Asp]	SID 121
7C repeats															
4a	B73	CEF-217	[Ser]	[Asp]	[Ile]	[Pro]	[Met]	[Ser]	[Gly]	[Ser]	[Asp]	[Ile]	[Pro]	SID 122	
5	CEF-35	B37	[Ser]	[Asp]	[Ile]	[Pro]	[Met]	[Ser]	[Gly]	[Ser]	[Asp]	[Ile]	[Pro]	SID 123	
5	CEF-28	B30	[Ser]	[Asp]	[Ile]	[Pro]	[Met]	[Ser]	[Gly]	[Ser]	[Asp]	[Ile]	[Pro]	SID 124	
3t	G5	CEF-103	[Ile]	[Asp]	[Ile]	[Gly]	[Ala]	[Ile]	[Met]	[Ile]	[Asp]	[Ile]	[Gly]	SID 125	
3t	G7	CEF-105	[Ile]	[Ser]	[Asp]	[Ile]	[Gly]	SID 126							
3a	B93	CEF-230	[Ile]	[Asp]	[Ile]	[Ile]	[Val]	[Ser]	[Ile]	[Ile]	[Asp]	[Ile]	[Ser]	SID 127	
5	CEF-30	B32	[Ile]	[Asp]	[Ile]	[Ile]	[Ile]	[Ile]	[Ile]	[Ile]	[Asp]	[Ile]	[Ser]	SID 128	
4a	B72	CEF-216	[Ser]	[Asp]	[Met]	[Ala]	[Ile]	[Ser]	[Pro]	[Ser]	[Asp]	[Ile]	[Pro]	SID 129	
5	CEF-23	B25	[Ser]	[Asp]	[Met]	[Ala]	[Ile]	[Ser]	[Pro]	[Ser]	[Asp]	[Ile]	[Pro]	SID 130	
5	CEF-33	B35	[Ala]	[Ile]	[Val]	[Ile]	[Asp]	[Asn]	[Ser]	[Ala]	[Ile]	[Val]	[Ile]	SID 131	
5	CEF-25	B27	[Ala]	[Ile]	[Val]	[Ile]	[Asn]	[Asp]	[Ser]	[Ala]	[Ile]	[Val]	[Ile]	SID 132	
5	CEF-37	B39	[Val]	[Ile]	[Gly]	[Gly]	[Gly]	[Ala]	[Pro]	[Leu]	[Val]	[Ile]	[Gly]	SID 133	
5	CEF-29	B31	[Val]	[Ile]	[Val]	[Gly]	[Gly]	[Ala]	[Pro]	[Leu]	[Val]	[Ile]	[Gly]	SID 134	
5	CEF-22	B24	[Val]	[Ile]	[Val]	[Gly]	[Gly]	[Ala]	[Pro]	[Leu]	[Val]	[Ile]	[Gly]	SID 135	
3a	B96	CEF-234	[Ile]	[Asp]	[Ile]	[Val]	[Asp]	[Ile]	[Pro]	[Pro]	[Pro]	[Pro]	[Pro]	SID 136	
4	G	CEF-158	[Ala]	[Ile]	[Val]	[Asp]	[Asp]	[Ile]	[Ile]	[Pro]	[Pro]	[Pro]	[Pro]	SID 137	
4	G	CEF-149	[Ala]	[Ile]	[Val]	[Ala]	[Ile]	[Asp]	[Val]	[Ile]	[Ile]	[Ile]	[Ile]	SID 138	

Fig 7

Biopan 4 Lead Sulfide

Biopan 5 Lead Sulphide

Fig. 8




Fig. 9a




Fig. 9b




Fig. 10. (a) POM image of smectic suspension of A7-ZnS suspension(127mg/ml), (b) cholesteric phase of A7-znS suspension, (c) AFM image of 25% of smectic suspension cast film, (d) SEM image of (a) suspension, (e) TEM image of individual bacteriophage binding with nanoparticle and (f) TEM image of 0.1 % dilute A7-ZnS suspension stained by 2% uranyl acetate and electron diffraction of ZnS wurtzite (inset).




Fig 11. (a) A photograph of M13 bacteriophage-ZnS nanoparticle biofilm, (b) a schematic diagram of structure of the film, (c) AFM image of the free surface of the film, (d) SEM image of the film, and (e,f) TEM image of nanoparticle alignment shows x-z, and y-z planes respectively

SEQUENCE LISTING

<110> Belcher, Angela M.
Lee, Seung-Wuk

<120> NANOSCALING ORDERING OF HYBRID MATERIALS USING GENETICALLY
ENGINEERED MESOSCALE VIRUS

<130> 119927-1051

<140> 10/157,775
<141> 2002-05-29

<150> 60/326,583
<151> 2001-10-02

<160> 95

<170> PatentIn version 3.1

<210> 1
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> artificial peptide

<400> 1

Ala Met Ala Gly Thr Thr Ser Asp Pro Ser Thr Val
1 5 10

<210> 2
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 2

Ala Ala Ser Pro Thr Gln Ser Met Ser Gln Ala Pro
1 5 10

<210> 3
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 3

His Thr His Thr Asn Asn Asp Ser Pro Asn Gln Ala
1 5 10

<210> 4
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 4

Asp Thr Gln Gly Phe His Ser Arg Ser Ser Ser Ala
1 5 10

<210> 5
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 5

Thr Ser Ser Ser Ala Leu Gln Pro Ala His Ala Trp
1 5 10

<210> 6
<211> 12
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 6

Ser Glu Ser Ser Pro Ile Ser Leu Asp Tyr Arg Ala
1 5 10

<210> 7

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 7

Ser Thr His Asn Tyr Gln Ile Pro Arg Pro Pro Thr
1 5 10

<210> 8

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 8

His Pro Phe Ser Asn Glu Pro Leu Gln Leu Ser Ser
1 5 10

<210> 9

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 9

Gly Thr Leu Ala Asn Gln Gln Ile Phe Leu Ser Ser
1 5 10

<210> 10
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 10

His Gly Asn Pro Leu Pro Met Thr Pro Phe Pro Gly
1 5 10

<210> 11
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 11

Arg Leu Glu Leu Ala Ile Pro Leu Gln Gly Ser Gly
1 5 10

<210> 12
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 12

Cys His Ala Ser Asn Arg Leu Ser Cys
1 5

<210> 13
<211> 12
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 13

Ser Met Asp Arg Ser Asp Met Thr Met Arg Leu Pro
1 5 10

<210> 14

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 14

Gly Thr Phe Thr Pro Arg Pro Thr Pro Ile Tyr Pro
1 5 10

<210> 15

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 15

Gln Met Ser Glu Asn Leu Thr Ser Gln Ile Glu Ser
1 5 10

<210> 16

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 16

Asp Met Leu Ala Arg Leu Arg Ala Thr Ala Gly Pro
1 5 10

<210> 17
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 17

Ser Gln Thr Trp Leu Leu Met Ser Pro Val Ala Thr
1 5 10

<210> 18
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 18

Ala Ser Pro Asp Gln Gln Val Gly Pro Leu Tyr Val
1 5 10

<210> 19
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 19

Leu Thr Trp Ser Pro Leu Gln Thr Val Ala Arg Phe
1 5 10

<210> 20
<211> 12

<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 20

Gln Ile Ser Ala His Gln Met Pro Ser Arg Pro Ile
1 5 10

<210> 21
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 21

Ser Met Lys Tyr Asn Leu Ile Val Asp Ser Pro Tyr
1 5 10

<210> 22
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 22

Gln Met Pro Ile Arg Asn Gln Leu Ala Trp Pro Met
1 5 10

<210> 23
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 23

Thr Gln Asn Leu Glu Ile Arg Glu Pro Leu Thr Pro
1 5 10

<210> 24

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 24

Tyr Pro Met Ser Pro Ser Pro Tyr Pro Tyr Gln Leu
1 5 10

<210> 25

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 25

Ser Phe Met Ile Gln Pro Thr Pro Leu Pro Pro Ser
1 5 10

<210> 26

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 26

Gly Leu Ala Pro His Ile His Ser Leu Asn Glu Ala
1 5 10

<210> 27
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 27

Met Gln Phe Pro Val Thr Pro Tyr Leu Asn Ala Ser
1 5 10

<210> 28
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 28

Ser Pro Gly Asp Ser Leu Lys Lys Leu Ala Ala Ser
1 5 10

<210> 29
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 29

Gly Tyr His Met Gln Thr Leu Pro Gly Pro Val Ala
1 5 10

<210> 30
<211> 12
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 30

Ser Leu Thr Pro Leu Thr Thr Ser His Leu Arg Ser
1 5 10

<210> 31

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 31

Thr Leu Thr Asn Gly Pro Leu Arg Pro Phe Thr Gly
1 5 10

<210> 32

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 32

Leu Asn Thr Pro Lys Pro Phe Thr Leu Gly Gln Asn
1 5 10

<210> 33

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 33

Cys Asp Leu Gln Asn Tyr Lys Ala Cys
1 5

<210> 34
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 34

Cys Arg His Pro His Thr Arg Leu Cys
1 5

<210> 35
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 35

Cys Ala Asn Leu Lys Pro Lys Ala Cys
1 5

<210> 36
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 36

Cys Tyr Ile Asn Pro Pro Lys Val Cys
1 5

<210> 37
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 37

Cys Asn Asn Lys Val Pro Val Leu Cys
1 5

<210> 38

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 38

Cys His Ala Ser Lys Thr Pro Leu Cys
1 5

<210> 39

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 39

Cys Ala Ser Gln Leu Tyr Pro Ala Cys
1 5

<210> 40

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 40

Cys Asn Met Thr Gln Tyr Pro Ala Cys
1 5

<210> 41
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 41

Cys Phe Ala Pro Ser Gly Pro Ala Cys
1 5

<210> 42
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 42

Cys Pro Val Trp Ile Gln Ala Pro Cys
1 5

<210> 43
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 43

Cys Gln Val Ala Val Asn Pro Leu Cys
1 5

<210> 44
<211> 9

<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 44

Cys Gln Pro Glu Ala Met Pro Ala Cys
1 5

<210> 45
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 45

Cys His Pro Thr Met Pro Leu Ala Cys
1 5

<210> 46
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 46

Cys Pro Pro Phe Ala Ala Pro Ile Cys
1 5

<210> 47
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 47

Cys Asn Lys His Gln Pro Met His Cys
1 5

<210> 48

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 48

Cys Phe Pro Met Arg Ser Asn Gln Cys
1 5

<210> 49

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 49

Cys Gln Ser Met Pro His Asn Arg Cys
1 5

<210> 50

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 50

Cys Asn Asn Pro Met His Gln Asn Cys
1 5

<210> 51
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 51

Cys His Met Ala Pro Arg Trp Gln Cys
1 5

<210> 52
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 52

His Val His Ile His Ser Arg Pro Met
1 5

<210> 53
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 53

Leu Pro Asn Met His Pro Leu Pro Leu
1 5

<210> 54
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 54

Leu Pro Leu Arg Leu Pro Pro Met Pro
1 5

<210> 55

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 55

His Ser Met Ile Gly Thr Pro Thr Thr
1 5

<210> 56

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 56

Ser Val Ser Val Gly Met Lys Pro Ser
1 5

<210> 57

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 57

Leu Asp Ala Ser Phe Met Gln Asp Trp
1 5

<210> 58
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 58

Thr Pro Pro Ser Tyr Gln Met Ala Met
1 5

<210> 59
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 59

Tyr Pro Gln Leu Val Ser Met Ser Thr
1 5

<210> 60
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 60

Gly Tyr Ser Thr Ile Asn Met Tyr Ser
1 5

<210> 61
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 61

Asp Arg Met Leu Leu Pro Phe Asn Leu
1 5

<210> 62

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 62

Ile Pro Met Thr Pro Ser Tyr Asp Ser
1 5

<210> 63

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 63

Met Tyr Ser Pro Arg Pro Pro Ala Leu
1 5

<210> 64

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 64

Gln Pro Thr Thr Asp Leu Met Ala His
1 5

<210> 65
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 65

Ala Thr His Val Gln Met Ala Trp Ala
1 5

<210> 66
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 66

Ser Met His Ala Thr Leu Thr Pro Met
1 5

<210> 67
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 67

Ser Gly Pro Ala His Gly Met Phe Ala
1 5

<210> 68
<211> 9

<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 68

Ile Ala Asn Arg Pro Tyr Ser Ala Gln
1 5

<210> 69
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 69

Val Met Thr Gln Pro Thr Arg
1 5

<210> 70
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 70

His Met Arg Pro Leu Ser Ile
1 5

<210> 71
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 71

Leu Thr Arg Ser Pro Leu His Val Asp Gln Arg Arg
1 5 10

<210> 72

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 72

Val Ile Ser Asn His Ala Glu Ser Ser Arg Arg Leu
1 5 10

<210> 73

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 73

His Thr His Ile Pro Asn Gln
1 5

<210> 74

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 74

Leu Ala Pro Val Ser Pro Pro
1 5

<210> 75
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 75

Cys Met Thr Ala Gly Lys Asn Thr Cys
1 5

<210> 76
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 76

Cys Gln Thr Leu Trp Arg Asn Ser Cys
1 5

<210> 77
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 77

Cys Thr Ser Val His Thr Asn Thr Cys
1 5

<210> 78
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> peptide

<400> 78

Cys Pro Ser Leu Ala Met Asn Ser Cys
1 5

<210> 79

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 79

Cys Ser Asn Asn Thr Val His Ala Cys
1 5

<210> 80

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 80

Cys Leu Pro Ala Gln Gly His Val Cys
1 5

<210> 81

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> peptide

<400> 81

Cys Leu Pro Ala Gln Val His Val Cys
1 5

<210> 82
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 82

Cys Pro Pro Lys Asn Val Arg Leu Cys
1 5

<210> 83
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 83

Cys Pro His Ile Asn Ala His Ala Cys
1 5

<210> 84
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 84

Cys Ile Val Asn Leu Ala Arg Ala Cys
1 5

<210> 85
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 85

Thr Met Gly Phe Thr Ala Pro Arg Phe Pro His Tyr
1 5 10

<210> 86
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 86

Ala Thr Gln Ser Tyr Val Arg His Pro Ser Leu Gly
1 5 10

<210> 87
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 87

Thr Ser Thr Thr Gln Gly Ala Leu Ala Tyr Leu Phe
1 5 10

<210> 88
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 88

Asp Pro Pro Trp Ser Ala Ile Val Arg His Arg Asp
1 5 10

<210> 89
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 89

Phe Asp Asn Lys Pro Phe Leu Arg Val Ala Ser Glu
1 5 10

<210> 90
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 90

His Gln Ser His Thr Gln Gln Asn Lys Arg His Leu
1 5 10

<210> 91
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 91

Thr Ser Thr Thr Gln Gly Ala Leu Ala Tyr Leu Phe
1 5 10

<210> 92
<211> 12

<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 92

Lys Thr Pro Ile His Thr Ser Ala Trp Glu Phe Gln
1 5 10

<210> 93
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 93

Asp Leu Phe His Leu Lys Pro Val Ser Asn Glu Lys
1 5 10

<210> 94
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 94

Lys Pro Phe Trp Thr Ser Ser Pro Asp Val Met Thr
1 5 10

<210> 95
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> peptide

<400> 95

Pro Trp Ala Ala Thr Ser Lys Pro Pro Tyr Ser Ser
1 5 10

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is positioned horizontally across the page, consisting of vertical black lines of varying widths on a white background.

**(43) International Publication Date
10 April 2003 (10.04.2003)**

PCT

(10) International Publication Number
WO 2003/029431 A3

(51) International Patent Classification⁷: C12Q 1/70, 1/68

) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2002/031655

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 2 October 2002 (02.10.2002)

English

(26) Publication Language: English

- 2 -

— with international search report

(30) Priority Data: 60/326,583 2 October 2001 (02.10.2001) US

(88) Date of publication of the international search report:
7 October 2004

(71) **Applicant:** BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).


(72) Inventors: BELCHER, Angela, M.; 35 Balfour Street, Lexington, MA 02421 (US). LEE, Seung-Wuk; 3350 Lake Austin Boulevard A, Austin, Texas 78703 (US).

(74) **Agents:** MAEBIUS, Stephen, B. et al.; Foley & Lardner,
3700 K Street N.W., Suite 500, Washington, DC 20007-
5143 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NANOSCALING ORDERING OF HYBRID MATERIALS USING GENETICALLY ENGINEERED MESOSCALE VIRUS

WO 2003/029431 A3



Soy ID No 1
Soy ID No 2
Soy ID No 3
Soy ID No 4
Soy ID No 5
Soy ID No 6
Soy ID No 7
Soy ID No 8
Soy ID No 9
Soy ID No 10
Soy ID No 11

(57) Abstract: The present invention includes methods for producing nanocrystals of semiconductor material that have specific crystallographic features such as phase and alignment by using a self-assembling biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to semi-conductor material. One form of the present invention is a method to construct ordered nanoparticles within the liquid crystal of the self-assembling biological molecule.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/31655

CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/70, 1/68
 US CL : 435/4, 5, 6, Dig. 3, Dig. 2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 5, 6, Dig. 3, Dig. 2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS, West

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	NIIKURA, K Ordering of inorganic nanocrystals using viruses Kagaku to Kogyo (Tokyo, Japan), 2002, Vol. 55, No. 2, page 1363, see the abstract	1-10 and 24
Y	Whaley, S. R. Borrowing ideas from nature: peptide-specific binding to gallium arsenide. Materials Research Society Symposium Proceedings, 2000, 599, pages 189-199, especially pages 190-196.	1-10, 24
X	WHALEY, S.R. Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly. Nature (London), 2000, Vol. 405, No. 6787, pages 665-668, especially pages 665 up to 668.	1-10, 24
Y	US 2002/0107179 (POTTS et al) 03 August 2002 (06.06.02) , entire document.	1-10, 24
Y	US 2001/0008759 A1 (MARKS et al) 19 July 2001 (19.07.02), column 5, [0051], column6 [0057].	1-10, 24
P, Y	US 6,329,209 B1 (WAGNER et al) 11 December 2001 (11.09.2001), column 38, line 30 up to column 43, line 20.	1-10, 24

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 April 2004 (19.04.2004)

Date of mailing of the international search report

14 JUL 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 Facsimile No. (703)305-3230

Authorized officer

T.D. Wessendorf

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/31655

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10 and 24

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-10 and 24, drawn to a method of making a film.

Group II, claim(s) 11-23 and 25, drawn to a method of controlling the cholesteric pitch of a nanoparticle.

Group III, claim(s) 26-36, drawn to a method of making a nanoparticle.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the methods lack the corresponding technical features as each method are drawn to different processes of making e.g., in Group I a film while Group III to a nanoparticle. Group II relates to a control of cholesteric pitch albeit, it does not recite said controlling step.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)